Orphan medicines have become a formidable R&D segment with robust growth that is expected to continue. Expansion is needed to cope with the issues of development and patient recruitment. An understanding of regulations, therefore, is critical.
llya Kurdyumov, PhD
Advertisement
Articles by llya Kurdyumov, PhD
Advertisement
Latest Updated Articles
Orphan Drugs: Market Overview and Country-Specific AnalysisApril 12th 2016
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
3
Where AI Governance in Clinical Development Falls Short
4
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
5